Aptar Q2 sales rise 6% to $966 mln, beat estimates

AptarGroup

31/07/2025 22:10

Overview

Aptar Q2 sales rise 6% yr/yr to $966 mln, beating analyst expectations

Adjusted EPS for Q2 beats consensus, rising 18% to $1.66

Co returns $100 mln to shareholders via dividends and share repurchases

Outlook

Aptar expects Q3 EPS between $1.53 and $1.61

Aptar sees challenges from normalizing naloxone sales

Company expects modest Q3 contributions from Closures and Beauty

Result Drivers

PHARMA SEGMENT - Strong demand in Prescription, Injectables, and Active Material Science divisions drove sales growth

BEAUTY SEGMENT - Growth in personal care products offset by lower demand in beauty dispensing technologies due to tariff uncertainties

CLOSURES SEGMENT - Increased demand in food and beverage markets across regions and applications fueled sales growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
Beat
$966 mln
$956 mln (5 Analysts)
Q2 Adjusted EPS
Beat
$1.66
$1.56 (6 Analysts)
Q2 EPS
$1.67
Q2 Net Income
$112 mln
Q2 Adjusted EBITDA
Beat
$218 mln
$210.50 mln (5 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the non-paper containers & packaging peer group is "buy"

Wall Street's median 12-month price target for Aptargroup Inc is $175.00, about 10.2% above its July 31 closing price of $157.14

The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 26 three months ago

Press Release: ID:nBw8Xy1s8a

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)